The Readout Loud
351: It's gonna be May (in biotech)
May 1, 2025
Join Gideon Gil, Managing Editor at STAT, and Zach Tracer, Senior Editor at STAT, as they explore major shifts in the biotech landscape following the Trump administration's first 100 days. They delve into the recent resurgence of biotech mergers and acquisitions and highlight the impressive launches of new drugs. The discussion also touches on Eli Lilly's challenges regarding patient access and the competitive dynamics with Novo Nordisk. Humorously, they juxtapose industry insights with pop culture, featuring a nod to a Justin Timberlake meme.
35:19
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The Trump administration's first 100 days caused significant disruptions in federal health agencies, resulting in fewer research grants and halted projects.
- A resurgence in biotech mergers and acquisitions signals market recovery, with notable deals indicating increased confidence in the industry's future.
Deep dives
The Impact of the Trump Administration on Health Agencies
The first 100 days of the Trump administration significantly disrupted federal health agencies and the biotech industry. Key changes included a substantial reduction in staff at the FDA, NIH, and CDC, leading to halted research grants and canceled advisory committee meetings. Reports indicate that the NIH approved $2.3 billion fewer new grants during this period compared to previous administrations, impacting funding for vital research. These shifts have created an atmosphere of uncertainty, compelling many universities to freeze hiring and admissions, further destabilizing the scientific community.
